SLS
SLS
NASDAQ · Biotechnology

Sellas Life Sciences Group I

$11.49
-0.04 (-0.35%)
As of Sep 20, 10:25 PM ET ·
Analyst Consensus
Strong Buy
6
Analysts
Moderate
Coverage
Buy 5 83%
Hold 1 17%
Sell 0 0%
Price Target
Analyst Price Target +195.0% upside
Low Target $25.20
Average Target $33.90
High Target $43.49
Current Price $11.49
Current
$11.49
Target
$33.90
$25.20 $33.90 avg $43.49
Scenario Analysis
Bear Case
$25.20
119.3%
Low target
Base Case
$33.90
+195.0%
Avg target
Bull Case
$43.49
+278.5%
High target
Risk/Reward
2.3x
Favorable
Price in Context
52-Week High
$15.88
-27.6% from high
52-Week Low
$1.39
+726.6% from low
Target vs 52W High
$33.90
+113.5% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 82% $257.58 -2.6%
AMGN
Amgen Inc
Hold 43 47% $190.87 -51.5%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +140.9%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 36 81% $438.34 -14.2%
REGN
Regeneron Pharmaceuticals
Buy 38 68% $76.80 -90.4%
MRNA
Moderna Inc
Hold 30 37% $149.45 -13.6%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -61.4%
RVMD
Revolution Medicines Inc
Strong Buy 28 93% $114.11 -40.8%